Universitätsklinikum Heidelberg

MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study (2018) Raab MS, Chatterjee M, Goldschmidt H, Agis H, Blau I, Einsele H, Engelhardt M, et al. Conference contribution Prospective Clinical Phase II Results on Treosulfan-Based Conditioning Treatment of 70 Paediatric Patients with Haematological Malignancies (2018) Kalwak K, Bader P, Styczynski J, Gruhn B, Patrick K, Sedlacek P, Stachel D, et al. Conference contribution Infection and Predictors of Outcome of Cirrhotic Patients after Emergency Care Hospital Admission (2018) Safi W, Elnegouly M, Schellnegger R, Umgelter K, Geisler F, Reindl W, Saugel B, et al. Journal article European myeloma network recommendations on tools for the diagnosis and monitoring of multiple myeloma: What to use and when (2018) Caers J, Garderet L, Kortuem KM, O'Dwyer ME, Van De Donk NWCJ, Binder M, Dold SM, et al. Journal article MRI-based high-precision irradiation in an orthotopic pancreatic tumor mouse model: A treatment planning study MRT-basierte Hochpräzisionsstrahlentherapie im orthotopen Pankreastumor-Mausmodell: Eine Bestrahlungsplanungsstudie (2018) Dobiasch S, Kampfer S, Habermehl D, Duma MN, Felix K, Strauss A, Schilling D, et al. Journal article Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility (2018) Machiela MJ, Gruenewald TGP, Surdez D, Reynaud S, Mirabeau O, Karlins E, Rubio RA, et al. Conference contribution Real-world effectiveness of ribociclib 1 aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study (2018) Fasching P, Decker T, Guderian G, Heim J, Jackisch C, Lueck HJ, Lueftner D, et al. Conference contribution Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms (2018) Apostolidis L, Kreutzfeldt S, Oles M, Gieldon L, Heining C, Horak P, Hutter B, et al. Conference contribution Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- nd RIG-1 agonist in patients with advanced solid tumors (2018) Terheyden P, Weishaupt C, Heinzerling L, Klinkhardt U, Krauss J, Mohr P, Kiecker F, et al. Conference contribution Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) (2018) Bringhen S, Milan A, Ferri C, Waesch R, Gay F, Larocca A, Salvini M, et al. Journal article, Review article